Sector News

Bellicum buys into CAR-T manufacturing amid a hot immuno-oncology race

May 8, 2015
Life sciences
Following the lead of Juno Therapeutics and Kite Pharma, CAR-T contender Bellicum Pharmaceuticals ($BLCM) is splashing cash on an in-house manufacturing operation, speeding its cell therapies into clinical trials in a host of cancers.
 
The biotech has leased a 27,000-square-foot manufacturing site that can churn out the modified T cells needed for so-called CAR-T therapies, which soup up patients’ immune systems to fight cancer. The new facility will sit on Bellicum’s Houston campus, adjacent to the Texas Medical Center, the company said.
 
CAR-T rivals Juno and Kite each made similar splashes on manufacturing this year, believing that the complex process of crafting cell therapies is best done internally and not left to contractors. Novartis, a leader in the space, has built dedicated facilities of its own, and each company is pursuing a fleet of clinical trials in hopes of establishing CAR-T’s promise in more and more indications.
 
“Bringing manufacturing in-house allows us to build upon our process and assay development expertise and streamline the production of our cell therapy product candidates, under our full control,” Bellicum CEO Tom Farrell said in a statement. “The planned facility is intended to provide study drug for clinical studies of BPX-501 and to support the development of our expanding pipeline of TCR and CAR-T adoptive cell therapy product candidates.”
 
BPX-501, a T cell therapy designed to ward off graft-versus-host disease in patients undergoing stem cell transplants, is Bellicum’s most advance asset, and the company has applied the same technology to oncology. Bellicum’s cancer pipeline includes BPX-401, a CAR-T candidate targeting the CD19 antigen, which is expressed by hematological cancer cells. Following that is BPX-601, another CAR-T that targets solid tumors, and BPX-701, an immunotherapy for skin cancer.
 
Each of the company’s cell therapies is equipped with a “safety switch” Bellicum says can mute unwanted transplant reactions like cytokine release syndrome, a common response to CAR-T therapy that has occasionally proven fatal in early studies. That feature, the company is betting, will help its assets stand out in a fast-crowding field.
 
By Damian Garde
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.